Colorectal Cancer

Molecular characterisation of gastrointestinal tumours through genomic, transcriptomic and proteomic analysis (R. Salazar, V. Moreno).
Construction of molecular signatures for predicting colorectal cancer prognosis (R. Salazar).
Predictions of therapeutic response based on molecular tumour detection and subtype classification (R. Salazar)
New experimental therapeutic strategies to overcome resistance in colorectal cancer treatment (R. Salazar).
Research, evaluation and validation of new diagnostic biomarkers in colorectal cancer (V. Moreno).
Genetic and epigenetic determinants of susceptibility to CRC and chemotherapy toxicity (V. Moreno).
Improvement in cancer precision medication and biomarker identification using computational analysis and large-scale integration of molecular data. (X. Solé).
Stratification of CRC patients based on molecular characteristics and the level of immune-cell infiltration of their tumours (R. Sanz-Pamplona).
Microbiome-host interactions and colorectal cancer (V. Pimenoff, M. Obon, V. Moreno)

A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer.

Vermorken J, Cervantes A, Morsing P, Johansson K, Andersson T, Roest NL, Gullbo J, Salazar R
ANNALS OF ONCOLOGY (ISSN: 0923-7534) 2019

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.

Santos C, Azuara D, Viéitez JM, Páez D, Falcó E, Élez E, López-López C, Valladares M, Robles-Díaz L, García-Alfonso P, Bugés C, Durán G, Salud A, Navarro V, Capellá G, Aranda E, Salazar R
ANNALS OF ONCOLOGY (ISSN: 0923-7534) 2019

Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer.

Vermorken J, Cervantes A, Morsing P, Johansson K, Andersson T, Roest NL, Gullbo J, Salazar R
JOURNAL OF HEPATOLOGY (ISSN: 0168-8278) 2020

Risk of colorectal cancer in users of bisphosphonates: analysis of population-based electronic health records.

Ibáñez-Sanz G, Guinó E, Pontes C, Morros R, de la Peña-Negro LC, Quijada-Manuitt MÁ, Moreno V
EUROPEAN JOURNAL OF EPIDEMIOLOGY (ISSN: 0393-2990) 2020

Genetic and metabolomics screening towards the precision medicine in cancer prevention

Moreno Aguado, Victor Raul (Principal investigator (PI))

Funder:

• ASOCIACION ESPAÑOLA CONTRA EL CANCER

01/10/2018 - 30/09/2023

Estudio de las interacciones microbioma-anfitrión para la prevención del cáncer colorrectal (Colonbiome)

Moreno Aguado, Victor Raul (Principal investigator (PI))

Funder:

• FIS-Instituto de Salud Carlos III

01/01/2018 - 31/12/2020

Phase II, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer

Ruffinelli Rodríguez, José Carlos (Principal investigator (PI))

Funder reference:

• W00090 GE 2 01

24/01/2019 - 24/01/2019

A randomized, multicentre, open-label controlled phase II trial of foxy-5 as neo-adjuvant therapy in subjects with WNT-5A low colon cancer

Santos Vivas, Cristina (Principal investigator (PI))

Funder reference:

• SMS-0472B

05/03/2019 - 05/03/2025

Estudio abierto, aleatorizado, fase 3 comparando Trifluridina/Tipiracilo (S95005) en ombinación con Bevacizumab y Capecitabina en combinación con Bevacizumab en primera línea de tratamiento de pacientes con cáncer colorrectal metastásico que no son candidatos a terapia intensiva (Estudio solstice)

Soler González, Gemma (Principal investigator (PI))

Funder reference:

• CL3-95005-006 (SOLSTICE)

11/06/2019 -

METODO PARA DETERMINAR EL RIESGO DE DESARROLLAR METASTASIS CEREBRAL Y UN KIT PARA LLEVAR A CABO DICHO PROCEDIMIENTO

SANZ PAMPLONA REBECA (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ ANGELS (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL BALDOMERO (Inventores-as/autores-as/obtentores-as); MORENO AGUADO VICTOR RAUL (Inventores-as/autores-as/obtentores-as); GIL GIL JUAN MIGUEL (Inventores-as/autores-as/obtentores-as)

METHOD FOR DETERMINING THE RISK OF DEVELOPING BRAIN METASTASIS, AND A KIT TO CARRY OUT SAID METHOD

Sanz Pamplona, Rebeca (Inventores-as/autores-as/obtentores-as); SIERRA JIMENEZ, Angels (Inventores-as/autores-as/obtentores-as); OLIVA MIGUEL, Baldomero (Inventores-as/autores-as/obtentores-as); Moreno Aguado, Victor Raul (Inventores-as/autores-as/obtentores-as); Gil Gil, Juan Miguel (Inventores-as/autores-as/obtentores-as)

See full list

Participation in international consortiums: MOTRICOLOR (Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer) and FIGI (Using functional genomics to inform gene environment interactions for CRC).
Colonomics as a platform for biomarker discovery and characterisation of CRC.
Clinical validation of ColoPrint®, a phase II prognostic genetic signature and new consensus on molecular subtype classification (CMS 1-4)